Skip to main content

Domain

The PWWP domain specifically recognizes and binds trimethylated 'Lys-36' of histone H3 (H3K36me3).

Function

Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MSH2 to form MutS alpha, which binds to DNA mismatches thereby initiating DNA repair. When bound, MutS alpha bends the DNA helix and shields approximately 20 base pairs, and recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. After mismatch binding, forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. Recruited on chromatin in G1 and early S phase via its PWWP domain that specifically binds trimethylated 'Lys-36' of histone H3 (H3K36me3): early recruitment to chromatin to be replicated allowing a quick identification of mismatch repair to initiate the DNA mismatch repair reaction.

Involvement in disease

Lynch syndrome 5

LYNCH5

A form of Lynch syndrome, an autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. Lynch syndrome is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, it is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical Lynch syndrome is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

None

The disease is caused by variants affecting the gene represented in this entry.

Endometrial cancer

ENDMC

A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.

None

Disease susceptibility is associated with variants affecting the gene represented in this entry.

Mismatch repair cancer syndrome 3

MMRCS3

An autosomal recessive form of mismatch repair cancer syndrome, a childhood cancer predisposition syndrome encompassing a broad tumor spectrum. This includes hematological malignancies, central nervous system tumors, Lynch syndrome-associated malignancies such as colorectal tumors as well as multiple intestinal polyps, embryonic tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature reminiscent of neurofibromatosis type 1, are often found as first manifestation of the underlying cancer.

None

The disease is caused by variants affecting the gene represented in this entry.

Colorectal cancer

CRC

A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

None

Disease susceptibility is associated with variants affecting the gene represented in this entry.

Post-translational modifications

The N-terminus is blocked.

Phosphorylated by PRKCZ, which may prevent MutS alpha degradation by the ubiquitin-proteasome pathway.

Sequence similarities

Belongs to the DNA mismatch repair MutS family.

Cellular localization

  • Nucleus
  • Chromosome
  • Associates with H3K36me3 via its PWWP domain.

Alternative names

GTBP, MSH6, DNA mismatch repair protein Msh6, hMSH6, G/T mismatch-binding protein, MutS protein homolog 6, MutS-alpha 160 kDa subunit, GTMBP, p160

Target type

Proteins

Primary research area

Oncology

Other research areas

  • Immuno-oncology

Molecular weight

152786Da

We found 28 products in 4 categories

Proteins & Peptides

Target

Species of origin

Multiplex Kits

Cell Lines & Lysates

Target

Cell type

Species or organism

Search our catalogue for 'MSH6' (28)

Products

ab92471

Anti-MSH6 antibody [EPR3945]

Recombinant
RabMAb
KO Validated

ab208940

Anti-MSH6 antibody [EPR20316]

Recombinant
RabMAb
KO Validated

ab99889

Anti-MSH6 antibody [SP93]

Recombinant
RabMAb
KO Validated

ab14204

Anti-MSH6 antibody [44]

KO Validated

ab251498

Anti-MSH6 antibody [EPR20316] - BSA and Azide free

Recombinant
RabMAb
KO Validated

ab214454

Anti-MSH6 antibody [EPR3945] - BSA and Azide free

Recombinant
RabMAb
KO Validated

ab238805

Anti-MSH6 antibody [SP93] - BSA and Azide free

Recombinant
RabMAb
KO Validated

ab198334

Alexa Fluor® 647 Anti-MSH6 antibody [EPR3945]

Recombinant
RabMAb
KO Validated

ab255410

Human MSH6 knockout HeLa cell line

Advanced Validation